Latest News

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Top Line Data Expected Year-End 2024 Pittsburgh, July 29, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain...

Blaqclouds Inc. Announces Launch of Groundbreaking Blockchain-Based AI Enterprise

Blaqclouds Inc. Announces Launch of Groundbreaking Blockchain-Based AI Enterprise

Las Vegas, NV, July 23, 2024— Blaqclouds Inc. (OTC: BCDS), is thrilled to announce the launch of its new blockchain-based AI enterprise. This cutting-edge initiative is set to revolutionize the landscape, enhancing data collection for blockchain operations and will...